A Randomized, Placebo-controlled, Double-blind, Multi-center, Phase 2 Study to Assess the Efficacy and Safety of CNTO 6785 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
Phase of Trial: Phase II
Latest Information Update: 01 Oct 2017
Price : $35 *
At a glance
- Drugs CNTO 6785 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus First in man; Proof of concept; Therapeutic Use
- Sponsors Janssen Research & Development; Janssen-Cilag
- 05 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 28 Apr 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 17 Mar 2015 Planned primary completion date changed from 1 Feb 2015 to 1 Nov 2015 as per ClinicalTrials.gov.